Who are Pteramina's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trimethoprim, Gentamicin, Wellcovorin, Klaron, Dapsone plus Adapalene, Methotrexate (tapering dose).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aminopterin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Pteramina — Competitive Intelligence Brief

Pteramina (AMINOPTERIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: aminopterin. Area: Oncology.

discontinued aminopterin Dihydrofolate reductase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pteramina (AMINOPTERIN). Pteramina works by inhibiting the enzyme dihydrofolate reductase, which is necessary for DNA synthesis and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pteramina TARGET	AMINOPTERIN		discontinued	aminopterin	Dihydrofolate reductase
Trimethoprim	TRIMETHOPRIM	Dr Reddys Labs Sa	marketed	Sulfonamide Antimicrobial [EPC]	Dihydrofolate reductase	1973-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	marketed	gentamicin	Dihydrofolate reductase	1970-01-01
Wellcovorin	leucovorin	Pfizer Japan Inc	marketed	Folate Analog	Dihydrofolate reductase	1952-01-01
Klaron	SULFACETAMIDE	Merck & Co.	marketed	Sulfonamide Antibacterial	Dihydrofolate reductase	1945-01-01
Dapsone plus Adapalene	Dapsone plus Adapalene	Allergan	marketed	Retinoid plus sulfone antibiotic combination	Retinoic acid receptors (adapalene); dihydrofolate reductase inhibition and neutrophil suppression (dapsone)
Methotrexate (tapering dose)	Methotrexate (tapering dose)	Hoffmann-La Roche	marketed	Antimetabolite / Folate antagonist	Dihydrofolate reductase (DHFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (aminopterin class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pteramina — Competitive Intelligence Brief. https://druglandscape.com/ci/aminopterin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab